Editor's Note

Endo International has been called a Valeant clone. They pursued an aggressive acquisition strategy to acquire drugs and then raise the prices for those drugs. They issued a massive guidance warning last week and revealed they were under investigation for the same issue that crashed Valeant.


NEW BULLISH Plays

No New Bullish Plays


NEW BEARISH Plays


ENDP - Endo Intl Plc - Company Description

Endo develops, manufactures and distributes pharmaceutical products and devices worldwide. The market well known brands including Percocet, Lidoderm, Voltaren and a wide range of pain medications and testosterone replacement therapies.

Shares have declined from $26 last week to $14 today. The company slashed full year guidance by -11% on revenue and -23% on earnings. The acceleration of the decline over the last several weeks has been in reaction to some generic competitors expected to receive approvals from the FDA soon.

The company also disclosed they were being investigated by the U.S. Attorney's Office for its relationship with pharmacy benefit managers or PBMs. In light of the improper relationship between Valeant and Philidor the USAO is investigating to see if the same problems exist at Endo. In November, Novartis had to pay a $390 million fine to settle charges it paid specialty pharmacies for illegal kickbacks in exchange for inducing patients to refill certain medications.

Endo is also under pressure as a result of the Valeant Pharmaceutical disaster and the overall decline in the biotech sector.

Earnings are August 4th.

Even though shares are down significantly from the May 6th news, I believe they will continue falling and could go into single digits. The similarities to Valeant's pharmacy problems and the impact to Valeant's stock are too close and should weigh on Endo.

Short ENDP shares, currently $13.54, initial stop loss $16.45

Optional

Buy long June $12.50 put, currently $1.05, initial stop loss $16.45.